Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
ORIGINAL

HLA genetic polymorphisms and prognosis of patients with COVID-19

L. Lorente a,∗, M.M. Martín b, A. Franco c, Y. Barrios d, J.J. Cáceres e, J. Solé-Violán f, A. Perez g, J.A. Marcos y Ramos h, L. Ramos-Gómez i, N. Ojeda j, A. Jiménez k, Working Group on COVID-19 Canary ICU l

a Intensive Care Unit, Hospital Universitario de Canarias, Ofra, s/n., La Laguna 38320, Santa Cruz de Tenerife, Spain
b Intensive Care Unit, Hospital Universitario Nuestra Señora de Candelaria, Crta del Rosario s/n., Santa Cruz de Tenerife 38010, Spain
c Immunology Unit of Laboratory Department, Hospital Universitario de Canarias, Ofra, s/n., La Laguna 38320, Santa Cruz de Tenerife, Spain
d Immunology Unit of Laboratory Department, Hospital Universitario de Canarias, Ofra, s/n., La Laguna 38320, Santa Cruz de Tenerife, Spain
e Intensive Care Unit, Hospital Insular, Plaza Dr. Pasteur s/n., Las Palmas de Gran Canaria 35016, Spain
f Intensive Care Unit, Hospital Universitario Dr. Negrín, Barranco de la Ballena s/n., Las Palmas de Gran Canaria 35010, Spain
g Internal Intensive Care Unit, Hospital Universitario de Canarias, Ofra, s/n., La Laguna 38320, Santa Cruz de Tenerife, Spain
h Intensive Care Unit, Hospital Doctor José Molina Orosa, Ctra. Arrecife-Tinajo, km 1.300, Arrecife, Lanzarote 35550, Spain
i Intensive Care Unit, Hospital General La Palma, Buenavista de Arriba s/n, Breña Alta, La Palma 38713, Spain
j Department of Anesthesiology, Hospital Universitario Dr. Negrín, Barranco de la Ballena s/n., Las Palmas de Gran Canaria 35010, Spain
k Research Unit, Hospital Universitario de Canarias, Ofra, s/n., La Laguna 38320, Santa Cruz de Tenerife, Spain

Received 9 June 2020; accepted 7 August 2020

KEYWORDS
HLA;
Genetic polymorphisms;
COVID-19;
Mortality;
Outcome

Abstract
Objective: Different genetic polymorphisms of human leukocyte antigen (HLA) have been associated with the risk and prognosis of autoimmune and infectious diseases. The objectives of this study were to determine whether there is an association between HLA genetic polymorphisms and the susceptibility to and mortality of coronavirus disease 2019 (COVID-19) patients.
Design: Observational and prospective study.
Setting: Eight Intensive Care Units (ICU) from 6 hospitals of Canary Islands (Spain).
Patients: COVID-19 patients admitted in ICU and healthy subjects.
Interventions: Determination of HLA genetic polymorphisms.
Main variable of interest: Mortality at 30 days.

∗ Corresponding author.
E-mail address: lorentemartin@msn.com (L. Lorente).
Please see a list of the members of the COVID-19 Canary ICU group in Appendix A.
**Results:** A total of 3886 healthy controls and 72 COVID-19 patients (10 non-survivors and 62 survivor patients at 30 days) were included. We found a trend to a higher rate of the alleles HLA-A*32 (p = 0.004) in healthy controls than in COVID-19 patients, and of the alleles HLA-B*39 (p = 0.02) and HLA-C*16 (p = 0.02) in COVID-19 patients than in healthy controls; however, all these p-values were not significant after correction for multiple comparisons. Logistic regression analysis showed that the presence of certain alleles was associated with higher mortality, such as the allele HLA-A*11 after controlling for SOFA (OR = 7.693; 95% CI = 1.063–55.650; p = 0.04) or APACHE-II (OR = 11.858; 95% CI = 1.524–92.273; p = 0.02), the allele HLA-C*01 after controlling for SOFA (OR = 11.182; 95% CI = 1.053–118.700; p = 0.04) or APACHE-II (OR = 17.604; 95% CI = 1.629–190.211; p = 0.02), and the allele HLA-DQ8*04 after controlling for SOFA (OR = 9.963; 95% CI = 1.235–80.358; p = 0.03).

**Conclusions:** The new finding from our preliminary study of small sample size was that HLA genetic polymorphisms could be associated with COVID-19 mortality; however, studies with a larger sample size before definitive conclusions can be drawn.

© 2020 Elsevier España, S.L.U. y SEMICYUC. All rights reserved.

**Polimorfismos genéticos de los HLA y pronóstico de pacientes con COVID-19**

**Resumen**

**Objetivo:** Diferentes polimorfismos genéticos de los antígenos leucocitarios humanos (HLA) están asociados con el riesgo y el pronóstico de enfermedades autoinmunes e infecciosas. Los objetivos de estudio fueron determinar si existe una asociación entre polimorfismos genéticos de HLA y la susceptibilidad y mortalidad de pacientes con la enfermedad del coronavirus 2019 (COVID-19).

**Diseño:** Estudio observacional y prospectivo.

**Ámbito:** Ocho unidades de cuidados intensivos (UCI) de 6 hospitales de las Islas Canarias (España).

**Pacientes:** Pacientes COVID-19 ingresados en la UCI y sujetos sanos.

**Intervenciones:** Se determinaron los polimorfismos genéticos de los HLA.

**Variable de interés principal:** Mortalidad a los 30 días.

**Resultados:** Se incluyeron 3.886 sujetos sanos y 72 pacientes COVID-19 (10 fallecidos y 62 supervivientes a 30 días). Encontramos una tendencia a una mayor frecuencia de los alelos HLA-A*32 (p = 0.004) en sujetos sanos que en pacientes COVID-19, y de los alelos HLA-B*39 (p = 0.02) y HLA-C*16 (p = 0.02) en pacientes COVID-19 que en sujetos sanos; sin embargo, no fueron significativos al corregir por comparaciones múltiples. En la regresión logística encontramos que la presencia de ciertos alelos estuvo asociada con mayor mortalidad, como el alelo HLA-A*11 controlando por SOFA (OR = 7.693; IC del 95%: 1.063–55.650; p = 0.04) o APACHE-II (OR = 11.858; IC del 95%: 1.524–92.273; p = 0.02), el alelo HLA-C*01 controlando por SOFA (OR = 11.182; IC del 95%: 1.053–118.700; p = 0.04) o APACHE-II (OR = 17.604; IC del 95%: 1.629–190.211; p = 0.02) y el alelo HLA-DQ8*04 controlando por SOFA (OR = 9.963; IC del 95%: 1.235–80.358; p = 0.03).

**Conclusiones:** Los nuevos hallazgos de nuestro preliminar estudio de pequeño tamaño muestral fueron que determinados polimorfismos genéticos de los HLA podrían estar asociados con la mortalidad de pacientes COVID-19; sin embargo, son necesarios estudios de mayor tamaño muestral para concluirlo definitivamente.

© 2020 Elsevier España, S.L.U. y SEMICYUC. Todos los derechos reservados.
as the development of acute respiratory distress syndrome (ARDS).\textsuperscript{3-8}

Human Leukocyte Antigen (HLA), located in the short arm of human chromosome 6 (6p21.3), represents one of the most highly polymorphic systems in the human genome and plays a central role in the regulation of immune response. The HLA system include near to 27,000 alleles in three distinct classes of genes (Class I, II and III). Of the three classes of genes, HLA class I-A, B, C and class II-DR, DP, DQ play a crucial role in various immunological functions in human including antigen presentation to T lymphocytes and recognition of self and non-self proteins. HLA class I and II gene polymorphisms provide the strongest and most consistent alleles for autoimmune diseases susceptibility.\textsuperscript{9,10}

HLA plays a central role in antigen presentation and therefore different allelic polymorphism could be involved in the susceptibility to infectious diseases. Different genetic polymorphisms of HLA have been associated with predisposition and/or outcome of different infectious diseases such as hepatitis B virus (HBV), hepatitis C virus (HCV), Chikungunya, Dengue, influenza A(H1N1) and tuberculosis.\textsuperscript{11-30} In addition, a recently published study found a higher rate of some HLA alleles in 82 COVID-19 non-critically ill patients than in control subjects.\textsuperscript{31} However, we have not found data about HLA and prognosis of COVID-19 patients. Thus, the objectives of this study were to determine whether there is an association between HLA genetic polymorphisms and susceptibility to and mortality of COVID-19 patients.

Methods

Design and subjects

In this prospective and observational study participated 8 Intensive Care Units from 6 hospitals of Canary Islands (Spain). The study was conducted with the approval in all hospitals of the Ethics Committee (Protocol code CHUC-2020-26). The requirement for written informed consent of each patient was waived given that data were prospectively collected, the context of the rapid emergence of this infectious disease and the public health outbreak policy of forbid patient visits by the Government of Spain.

We included patients admitted to the ICU with laboratory-confirmed COVID-19 by means of a positive result for COVID-19 nucleic acids by a real-time fluorescence reverse transcription-polymerase chain reaction (RT-PCR) assay of a nasopharyngeal swab sample or a bronchial aspirate.

Determination of genetic polymorphisms of HLA

Genomic DNA was extracted from peripheral blood samples by using standard protocols in a Maxwell® Rapid Sample Concentrator (RSC) Instrument (Promega Corp, USA). HLA typing was performed by polymerase chain reaction sequence-specific oligonucleotide (PCR-SSO) technique developed by LIFECODES® HLA-SSO Typing (Immucor Inc, USA). We genotyped HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 loci in COVID-19 patients. We used as controls a group of healthy subject representative of the allele frequency of our population (Canary Islands) registered as voluntary donors in the Spanish Register of Bone Marrow Donors (REDMO is the acronym from Spain).

Variables recorded

We recorded the following variables regarding to demographic and clinical data: age, sex, body mass index, and history of chronic renal failure, diabetes mellitus, chronic obstructive pulmonary disease (COPD), active smoking, smoking cessation, chronic liver disease, ischemic heart disease, arterial hypertension, steroid agents, human immunodeficiency virus (HIV), solid tumor and hematological tumor. We also recorded body temperature, chest radiography findings, Acute Physiology and Chronic Health Evaluation (APACHE)-II score,\textsuperscript{32} Sepsis-related Organ Failure Assessment [SOFA] score\textsuperscript{33} and the development of ARDS.\textsuperscript{34}

Besides, we registered the following laboratory data at ICU admission: lactate, sodium, glucose, blood urea nitrogen, protein, albumin, creatine kinase, bilirubin, aspartate transaminase, alanine transaminase, lactate dehydrogenase, alkaline phosphatase, procalcitonin, C-reactive protein, interleukin-6, ferritin, hemoglobin, hematocrit, white blood cell, neutrophils, lymphocytes, platelets, activated partial thromboplastin time (aPTT), international normalized ratio (INR), d-dimer, fibrinogen, pressure of arterial oxygen (PaO\textsubscript{2}) and fraction of inspired oxygen (FiO\textsubscript{2}).

In respect to ICU treatment, respiratory support, prone position, neuromuscular blockers, lopinavir/ritonavir, interferon, hydroxichloroquine, tocilizumab, steroid agents, continuous and intermittent renal replacement therapy, and vasopressors were recorded. Survival at 30 days was our endpoint study.

Statistical methods

We used frequencies (percentages) and medians (percentile 25–75) to describe categorical and continuous variables. We used chi-square test and Mann–Whitney U test to compare categorical and continuous variables between patient groups (surviving and non-surviving). We tested the possible association between some HLA allele and 30-day mortality using logistic regression analysis, and Odds Ratio and its 95% confidence intervals were calculated as measurement of the clinical impact of the predictor variables. As 10 was the number of non-surviving patients at 30 days, we constructed several logistic regression models with only two predictor variables in each model to avoid over fitting effect.\textsuperscript{35} In each model was included one HLA allele and one clinical variable with p-value lower than 0.10 in the comparison between non-surviving and surviving patients. Thus, we performed six logistic regression models including HLA-A*11, HLA-C*01 and HLA-DQB1*04 as HLA alleles, and SOFA and APACHE-II as clinical variables. Hosmer–Lemeshow test was reported for each regression model. We used the point $p < 0.05$ for the establishment of significant differences, and the programs NCSS 2000 (Kaysville, Utah) and SPSS 17.0 (SPSS Inc., Chicago, IL, USA) for the analyses.
Results

Genotyping of HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 loci was performed in 3886 healthy controls and 72 COVID-19 patients (Supplementary Tables 1–5). We found a trend to a higher rate of the alleles HLA-A*32 (p = 0.004) in healthy controls than in COVID-19 patients, and of the alleles HLA-A*03 (p = 0.047), HLA-B*39 (p = 0.02) and HLA-C*16 (p = 0.02) in COVID-19 patients than in healthy controls; however, all these p-values no were significant after correction for multiple comparisons.

We found that non-surviving (n = 10) compared to surviving patients (n = 62) showed higher APACHE-II (p < 0.001) and SOFA (p < 0.001) (Tables 1 and 2). We found a trend to a higher rate of the alleles HLA-A*11 (p = 0.051), HLA-C*01 (p = 0.09) and HLA-DQB1*04 (p = 0.051) in non-surviving than in surviving patients (Supplementary Tables 1–5). Logistic regression analysis showed that the presence of allele HLA-A*11 was associated with higher mortality after controlling for SOFA (OR = 7.693; 95% CI = 1.063–55.650; p = 0.04) or APACHE-II (OR = 11.858; 95% CI = 1.524–92.273; p = 0.02). In addition, the allele HLA-C*01 was associated with higher mortality after controlling for SOFA (OR = 11.182; 95% CI = 1.053–118.700; p = 0.04) or APACHE-II (OR = 17.604; 95% CI = 1.629–190.211; p = 0.02). Besides, the presence of allele HLA-DQB1*04 was associated with higher mortality after controlling for SOFA (OR = 9.963; 95% CI = 1.235–80.358; p = 0.03), but no controlling for APACHE-II (Table 3).

Discussion

To our knowledge, this is the first study reporting data on HLA genetic polymorphisms and susceptibility to and prognosis in COVID-19 patients. We found a trend to a higher rate of alleles HLA-A*32 in healthy controls than in COVID-19 patients, and of alleles HLA-A*03, HLA-B*39 and HLA-C*16 in COVID-19 patients than in healthy controls. The small sample size of our COVID-19 population could explain the absence of significant differences after Bonferroni correction in those and other HLA genetic polymorphisms.

We found that non-surviving compared to surviving patients showed higher APACHE-II and SOFA. We also found a trend to higher rate of the alleles HLA-A*11, HLA-C*01 and HLA-DQB1*04 in non-surviving than in surviving patients. As previously mentioned, the small sample size of our study could have explained these results. Therefore, we decided performed regression analyses to test the potential association of those HLA alleles and mortality. As 10 was the number of non-surviving patients at 30 days, we constructed several multiple binomial logistic regression models with only two predictor variables in each model to avoid over fitting effect. We included HLA-A*11 and SOFA in the first model, HLA-A*11 and APACHE-II in the second model, HLA-C*01 and SOFA in the third model, HLA-C*01 and APACHE-II in the fourth model, HLA-DQB1*04 and SOFA in the fifth model, and HLA-DQB1*04 and APACHE-II in the sixth model. An important finding is that all 3 alleles were associated with the mortality after controlling for SOFA, and the same was observed for alleles HLA-A*11 and HLA-C*01 when controlled for APACHE-II.

The results of our study are in line with those of other studies in patients with other infectious diseases. Regarding to susceptibility, higher rate of HLA-A*32 has been found in patients with chronic HCV infection than in control subjects.11 A restricted response of cytotoxic T lymphocytes for HCV in presence of HLA-A*03 has been reported.12 Higher rate of HLA-B*39 was also found in patients with tuberculosis,13 Chagas disease14 and osteoarticular complications due to brucellosis15 in comparison with controls. There has been found higher rate of HLA-A*11 in patients with panbronchiolitis,17 dengue disease,18 HBV infection,19 influenza A(H1N1)pdm09 virus infection20 or invasive meningococcal disease than in control subjects.21 Higher frequency of HLA-C*01 has been found in patients with acute viral encephalitis than in control subjects.24 There has been found higher rate of HLA-DQB1*04 in patients with HBV,25 human papillomavirus (HPV) infection,26 post-histoplasmosis fibrosing mediastinitis27 or chikungunya viral infection encephalitis than in control subjects.28 In a recently published study has been found a higher rate of HLA-C*07:29 and HLA-B*15:27 in 82 COVID-19 non-critically ill patients than in control subjects.31 However, our study was underpowered to find an association between HLA genetic polymorphism and susceptibility to COVID-19 patients.

Interestingly, we found certain HLA genetic polymorphisms that could increase the risk of death in patients COVID-19. Previously, regarding to prognosis, the presence of HLA-C*16 increase the risk of rapid progression in patients with Acquired Immune Deficiency Syndrome.6 Also, the presence of HLA-A*11 has been associated with poor evolution of patients with HBV62 or active pulmonary tuberculosis.23 Besides, the presence of HLA-DQB1*04 has been associated with poor evolution of patients with HBV,29,30 however, to the best of our knowledge, no study has evaluated this aspect in patients with COVID-19.

We must recognize some limitations of our study. First, we only included two variables in each regression analysis model due to that the small number of death patients in our study, which precludes the inclusion of several variables,35 as previously has been reported in other researches.36,37 That small number of death patients in our study was due to the small sample size and to the low mortality rate in our series (14%), which was in the lower limit of the range published by other series from ICU of our country (15–34%).38–40 Second, we studied mortality at 30 days and mortality at other moment of time have been not studied. Third, the rate of SDRA was higher, not statistically significant, in survivor than in non-survivor patients, possibly due to the small sample size. However, we think that the strengths of the study were that two HLA alleles in our study (HLA-A*11 and HLA-C*01) were associated with the mortality after controlling for SOFA or APACHE-II. In addition, the three HLA alleles associated with the mortality in our study (HLA-A*11, HLA-DQB1*04 and HLA-C*01), previously were associated with poor evolution in other infectious diseases (HLA-A*11,22,23 and HLA-DQB1*0429,30) or with the risk of other infectious diseases (HLA-C*0124).
Table 1  Demographic and clinical data of non-surviving and surviving patients.

|                                      | Survivors (n = 62) | Non-survivors (n = 10) | P value |
|--------------------------------------|--------------------|------------------------|---------|
| Gender female – n (%)                | 34 (54.8)          | 7 (70.0)               | 0.50    |
| Age (years) – median (p 25–75)       | 65 (52–71)         | 70 (59–75)             | 0.16    |
| Body mass index (kg/m²)              | 28.0 (25.5–34.5)   | 26.1 (23.8–31.4)       | 0.30    |
| Diabetes mellitus – n (%)            | 15 (24.2)          | 1 (10.0)               | 0.44    |
| Chronic renal failure – n (%)        | 1 (1.6)            | 0                      | 0.99    |
| COPD – n (%)                         | 3 (4.8)            | 1 (10.0)               | 0.46    |
| Ischemic heart disease – n (%)       | 3 (4.8)            | 2 (20.0)               | 0.14    |
| Chronic liver disease – n (%)        | 1 (1.6)            | 0                      | 0.99    |
| Smoking cessation – n (%)            | 11 (17.7)          | 3 (30.0)               | 0.40    |
| Smoking – n (%)                      | 4 (6.5)            | 1 (10.0)               | 0.54    |
| Arterial hypertension – n (%)        | 26 (41.9)          | 4 (40.0)               | 0.99    |
| Steroid agents – n (%)               | 2 (3.2)            | 1 (10.0)               | 0.37    |
| Hematological tumor – n (%)          | 1 (1.6)            | 0                      | 0.99    |
| Solid tumor – n (%)                  | 1 (1.6)            | 0                      | 0.99    |
| Human Immunodeficiency Virus – n (%) | 1 (1.6)            | 0                      | 0.99    |
| Temperature (°C) – median (p 25–75)  | 37.0 (36.0–37.5)   | 36.4 (35.0–38.1)       | 0.83    |
| Chest radiography findings – n (%)   |                    |                        | 0.82    |
| Consolidation only                   | 6 (9.7)            | 1 (10.0)               |         |
| Ground glass opacity plus consolidation | 25 (40.3)         | 3 (30.0)               |         |
| Ground glass opacity only            | 31 (50.0)          | 6 (60.0)               |         |
| ARDS – n (%)                         | 55 (88.7)          | 7 (70.0)               | 0.14    |
| APACHE-II score – median (p 25–75)   | 12 (7–15)          | 18 (16–22)             | <0.001  |
| SOFA score – median (p 25–75)        | 3 (3–7)            | 8 (7–10)               | 0.001   |
| Lactic acid (mmol/L) – median (p 25–75) | 1.40 (1.00–1.90) | 1.90 (1.33–2.35)       | 0.17    |
| Glucose (g/dL) – median (p 25–75)    | 146 (108–192)      | 132 (124–221)          | 0.97    |
| Sodium (mEq/L) – median (p 25–75)    | 138 (135–142)      | 139 (134–142)          | 0.91    |
| Blood urea nitrogen (mg/dL) – median (p 25–75) | 19 (14–29) | 24 (16–28)             | 0.44    |
| Protein (g/L) – median (p 25–75)     | 6.5 (5.9–7.1)      | 5.9 (5.5–6.6)          | 0.50    |
| Albumin (g/L) – median (p 25–75)     | 3.0 (2.6–3.6)      | 3.9 (2.1–4.4)          | 0.37    |
| Creatine kinase (U/L) – median (p 25–75) | 138 (54–317)    | 316 (138–1274)         | 0.17    |
| Total bilirubin (mg/dL) – median (p 25–75) | 0.60 (0.40–1.23) | 0.70 (0.35–1.10)       | 0.91    |
| Aspartate transaminase (U/L) – median (p 25–75) | 41 (31–69)    | 55 (23–123)            | 0.66    |
| Alanine transaminase (U/L) – median (p 25–75) | 37 (27–57)    | 40 (25–59)             | 0.87    |
| Lactate dehydrogenase (U/L) – median (p 25–75) | 419 (302–480) | 327 (230–649)          | 0.56    |
| Alkaline phosphatase (U/L) – median (p 25–75) | 64 (50–86) | 86 (50–110)            | 0.51    |
| C-reactive protein (mg/ml) – median (p 25–75) | 26 (13–23)   | 26 (13–66)             | 0.60    |
| Procalcitonin (ng/ml) – median (p 25–75) | 0.21 (0.08–0.56) | 0.65 (0.16–2.21)       | 0.17    |
| Ferritin (μg/ml) – median (p 25–75)  | 1192 (800–1817)    | 977 (505–1184)         | 0.36    |
| Interleukin-6 (pg/ml) – median (p 25–75) | 38 (5–150) | 61 (24–140)            | 0.55    |
| Hemoglobin (g/dL) – median (p 25–75) | 12.8 (11.7–14.5)   | 13.6 (10.1–15.2)       | 0.78    |
| Hematocrit (%) – median (p 25–75)    | 39 (36–43)         | 41 (31–46)             | 0.74    |
| White blood cell – median*10³ /mm³ (p 25–75) | 8.4 (6.4–11.9) | 7.7 (5.1–12.3)         | 0.64    |
| Neutrophils – median*10³ /mm³ (p 25–75) | 7.3 (5.4–10.4) | 7.1 (3.6–8.8)          | 0.45    |
| Lymphocytes – median*10³ /mm³ (p 25–75) | 0.72 (0.55–1.00) | 0.97 (0.46–1.37)       | 0.36    |
| Platelets – median*10³ /mm³ (p 25–75) | 225 (173–299)    | 174 (131–284)          | 0.23    |
| INR – median (p 25–75)               | 1.14 (1.05–1.33)   | 1.25 (1.16–1.64)       | 0.10    |
| aPTT (seconds) – median (p 25–75)    | 31 (27–33)         | 34 (26–40)             | 0.26    |
| Fibrinogen (mg/dL) – median (p 25–75) | 727 (532–832) | 882 (560–910)          | 0.38    |
| D-dimer (ng/mL) – median (p 25–75)   | 1058 (588–2006)    | 945 (453–8000)         | 0.81    |
| PaO2/FI02 ratio – median (p 25–75)   | 136 (100–213)      | 111 (93–202)           | 0.63    |

COPD = Chronic Obstructive Pulmonary Disease; APACHE = Acute Physiology and Chronic Health Evaluation; SOFA = Sepsis-related Organ Failure Assessment; ARDS = acute respiratory distress syndrome; INR = International normalized ratio; aPTT = Activated partial thromboplastin time; PaO₂ = pressure of arterial oxygen; FI0₂ = fraction inspired oxygen.
Table 2  Treatment of non-surviving and surviving patients.

|                                | Survivors (n = 62) | Non-survivors (n = 10) | P value |
|--------------------------------|--------------------|------------------------|---------|
| Respiratory support – n (%)    |                    |                        | 0.38    |
| Conventional oxygen therapy    | 2 (3.2)            | 0                      |         |
| High-flow nasal cannula        | 7 (11.3)           | 0                      |         |
| Non-invasive mechanical ventilation | 6 (9.7)        | 0                      |         |
| Invasive mechanical ventilation| 47 (75.8)          | 10 (100)               |         |
| Neuromuscular blockers – n (%) |                    |                        | 0.99    |
| Prone position – n (%)         |                    |                        | 0.29    |
| Lopinavir/Ritonavir – n (%)    |                    |                        | 0.54    |
| Hydroxychloroquine – n (%)     |                    |                        |         |
| Interferon Beta 1-B – n (%)    |                    |                        | 0.68    |
| Tocilizumab – n (%)            |                    |                        | 0.73    |
| Steroid agents – n (%)         |                    |                        | 0.99    |
| Intermittent renal replacement therapy – n (%) | 1 (1.6) | 0 | 0.99 |
| Continuous renal replacement therapy – n (%) | 8 (12.9) | 3 (30.0) | 0.17 |

Table 3  Multiple logistic regression analyses to predict mortality at 30 days.

|                       | Chi-square | Degrees of freedom | Odds ratio | 95% confidence interval | P-value |
|-----------------------|------------|--------------------|------------|-------------------------|---------|
| Model 1:              |            |                    |            |                        |         |
| Hosmer and Lemeshow test | 2.621     | 7                  | 7.693      | 1.063–55.650            | 0.04    |
| HLA-A*11              |            |                    | 1.532      | 1.142–2.054             | 0.004   |
| SOFA score (points)   |            |                    |            |                        |         |
| Model 2:              |            |                    |            |                        |         |
| Hosmer and Lemeshow test | 5.006     | 8                  | 11.858     | 1.524–92.273            | 0.02    |
| HLA-A*11              |            |                    | 1.278      | 1.098–1.489             | 0.002   |
| APACHE-II (points)    |            |                    |            |                        |         |
| Model 3:              |            |                    |            |                        |         |
| Hosmer and Lemeshow test | 2.285     | 7                  | 11.182     | 1.053–118.700           | 0.04    |
| HLA-C*01              |            |                    | 1.551      | 1.161–2.072             | 0.003   |
| SOFA score (points)   |            |                    |            |                        |         |
| Model 4:              |            |                    |            |                        |         |
| Hosmer and Lemeshow test | 3.682     | 8                  | 17.604     | 1.629–190.211           | 0.02    |
| HLA-C*01              |            |                    | 1.297      | 1.099–1.531             | 0.002   |
| APACHE-II (points)    |            |                    |            |                        |         |
| Model 5:              |            |                    |            |                        |         |
| Hosmer and Lemeshow test | 3.569     | 7                  | 9.963      | 1.235–80.358            | 0.03    |
| HLA-DQB1*04           |            |                    | 1.555      | 1.156–2.091             | 0.004   |
| SOFA (points)         |            |                    |            |                        |         |
| Model 6:              |            |                    |            |                        |         |
| Hosmer and Lemeshow test | 4.548     | 8                  | 2.961      | 0.419–20.947            | 0.28    |
| HLA-DQB1*04           |            |                    | 1.230      | 1.066–1.420             | 0.005   |

SOFA = Sepsis-related Organ Failure Assessment; APACHE = Acute Physiology and Chronic Health Evaluation.

Conclusions

The new finding from our preliminary study of small sample size was that HLA genetic polymorphisms could be associated with COVID-19 mortality; however, studies with a larger sample size before definitive conclusions can be drawn.

Authors’ contributions

Llo conceived, designed and coordinated the study, participated in acquisition and interpretation of data, and drafted the manuscript.
Funding

This study was supported by a grant from Instituto de Salud Carlos III (PI-18-00500) (Madrid, Spain) and co-financed with Fondo Europeo de Desarrollo Regional (FEDER).

Conflicts of interest

The authors declare that they have no competing interests.

Appendix A. Investigators of Working Group of COVID-19 Canary ICU

Leonardo Lorente, Andrés Franco, Yaelise Barrios, Alina Perez, Alejandro Jiménez, Antonia Pérez-Cejas, Alejandra Pérez-Llombet, Luis Uribe, Lourdes González, Rocio Alvarez (Hospital Universitario de Canarias. La Laguna. Tenerife. Spain); María M. Martín, Julia Alcoba-Flórez, Albano Estupihan (Hospital Universitario Nuestra Señora de Candelaria. Santa Cruz de Tenerife. Spain); Juan J. Cáceres, Paula Vega, Lucía González (Hospital Insular. Las Palmas de Gran Canaria. Spain); Jordi Solé-Violán, Nazario Ojeda, Sergio López, Aurelio Rodríguez-Pérez, Casimira Dominguez (Hospital Universitario Dr. Negrín. Las Palmas de Gran Canaria. Spain); José Alberto Marcos y Ramos, María F. Zapata (Hospital Doctor José Molina Orosa. Lanzarote. Spain); Luis Ramos-Gómez, Raquel Ortiz-López (Hospital General La Palma. La Palma. Spain).

Appendix B. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.medin.2020.08.004.

References

1. World Meters. Coronavirus disease (COVID-19). https://www.worldometers.info/coronavirus/coronavirus-cases [accessed 8.06.20].
2. World Heart Organization. Coronavirus disease (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus -2019 [accessed 8.06.20].
3. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020, http://dx.doi.org/10.1007/s00134-020-05991-x [Epub ahead of print].
4. Liu W, Tao ZW, Lei W, Ming-Li Y, Kui L, Ling Z, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl). 2020, http://dx.doi.org/10.1097/CMD.0000000000000775 [Epub ahead of print].
5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.
6. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020, http://dx.doi.org/10.1001/jamainternmed.2020.0994 [Epub ahead of print].
7. Henry BM, de Oliveira MHS, Benoît S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020 [Epub ahead of print].
8. Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Euro J. 2020:55, http://dx.doi.org/10.1183/13993003.00524-2020, pii:2000524. Print 2020 May.
9. Zakharova MY, Belyamina TA, Sokolov AV, Kiselev IS, Mamedov AE. The contribution of major histocompatibility complex class II genes to an association with autoimmune diseases. Acta Nat. 2019;11:4–12.
10. Muñiz-Castrillo S, Vogrig A, Honnorat J. Associations between HLA and autoimmune neurological diseases with autoantibodies. Auto Immune Highlights. 2020;11:2.
11. Mosaad YM, Farag RE, Afroa MM, Eletreby S, El-Alfy HA, Eldeek BS, et al. Association of human leucocyte antigen Class I (HLA-A and HLA-B) with chronic hepatitis C virus infection in Egyptian patients. Scand J Immunol. 2010;72:548–53.
12. Koziel MJ, Dudley D, Afadh N, Grakoui A, Rice CM, Choo QL, et al. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest. 1995;96:2311–21.
13. Soto ME, Vargas-Alarcón G, Cicerò-Sabido R, Ramírez E, Alvarez-León E, Reyes PA. Comparison distribution of HLA-B alleles in mexican patients with takayasus arteritis and tuberculosis. Hum Immunol. 2007:68:449–53.
14. Cruz-Robles D, Reyes PA, Montén-Padilla VM, Ortiz-Muñiz AR, Vargas-Alarcón G. MHC class I and class II genes in Mexican patients with Chagas disease. Hum Immunol. 2004;65:60–5.
15. Bravo MJ, Colmenero Jde D, Alonso A, Caballero A. HLA-B*39 allele confers susceptibility to osteoarticular complications in human brucellosis. J Rheumatol. 2003;30:1051–3.
16. Hendel H, Caillat-Zucman S, Lебuanec H, Carrington M, O’Brien S, Andrieu JM, et al. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol. 1999;162:6942–6.
17. Keicho N, Hjikjata M. Genetic predisposition to diffuse panbronchiolitis. Respirol. 2011;16:581–8.
18. Stephens HA. HLA and other gene associations with dengue disease severity. Curr Top Microbiol Immunol. 2010;338:99–114.
19. Akcam Z, Sunbul M, Durupinar B, Eroglu C, Esen S, Leblebi- cioglu H. Tissue types as prognostic risk factor in hepatitis B virus infection. Indian J Gastroenterol. 2002;21:139–41.
20. Dutta M, Dutta P, Medhi S, Borkakoty B, Biswas D1. Polymorphism of HLA class I and class II alleles in influenza A(H1N1)pdm09 virus infected population of Assam, Northeast India. J Med Virol. 2018;90:854–60.
21. Holub M, Hobstová J, Pražák J, Pudil P. Association of class I HLA antigens with invasive meningococcal disease. Cas Lek Cesk. 1998;137:598–600.
22. Albayrak A, Ertek M, Tasyaran MA, Pirin I. Role of HLA allele polymorphism in chronic hepatitis B virus infection and HBV
vaccine sensitivity in patients from eastern Turkey. Biochem Genet. 2011;49:258–69.
23. Knörring BE, Berkos AS. Sakharova Ila. Distribution of histocompatibility antigens in patients with pulmonary tuberculosis depending on disease course and immune response pattern. Probl Tuberk. 1995;16–9.
24. Tuttolomondo A, Colomba C, Di Bona D, Casuccio A, Di Raimondo D, Clemente G, et al. HLA and killer cell immunoglobulin-like receptor (KIRs) genotyping in patients with acute viral encephalitis. Oncotarget. 2018;9:17523–32.
25. Ou G, Xu H, Yu H, Liu X, Yang L, Ji X, et al. The roles of HLA-DQB1 gene polymorphisms in hepatitis B virus infection. J Transl Med. 2018;16:362.
26. Zhao J, Wang L, Lin H, Yu W, Xu X, Hu H, et al. Association of HLA-DRB1/DQB1 polymorphism with high-risk HPV infection and cervical intraepithelial neoplasia women from Shanghai. Int J Clin Exp Pathol. 2018;11:748–56.
27. Strock SB, Gaudieri S, Mallal S, Yu C, Mitchell D, Cogan J, et al. Fibrosing mediastinitis complicating prior histoplasmosis is associated with human leukocyte antigen DQB1*04:02 – a case–control study. BMC Infect Dis. 2015;15:206.
28. Thanapati S, Hande A, Das R, Gurav Y, Tripathy AS. Association of human leukocyte antigen class II allele and haplotypes in chikungunya viral infection in a western Indian population. Trans R Soc Trop Med Hyg. 2014;108:277–82.
29. Chalub SR, da Silva RM, da Silva AP, de Aquino PF, Sadahiro A, Kalil AN. Evaluation of a histocompatibility antigen related to hepatitis B virus in patients with hepatocellular carcinoma in the western Brazilian Amazon. Genet Mol Res. 2013;12:1336–46.
30. Lai MW, Hsu CW, Lin CL, Chien RN, Lin WR, Chang CS, et al. Multiple doses of hepatitis B recombinant vaccine for chronic hepatitis B patients with low surface antigen levels: a pilot study. Hepatol Int. 2018;12:456–64.
31. Wang W, Zhang W, Zhang J, He J, Zhu F. Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease-2019 (COVID-19) [published online ahead of print, 2020 May 19]. HLA. 2020, http://dx.doi.org/10.1111/tan.13941.
32. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29.
33. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The Sepsis-related Organ Failure Assessment (SOFA) score to describe organ dysfunction/failure. Intensive Care Med. 1996;22:707–10.
34. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307:2526–33.
35. Kleinbaum DG, Kupper LL, Muller KE, Nizam A. Polynomial regression. In: Kleinbaum DG, Kupper LL, Muller KE, Nizam A, editors. Applied regression analysis and other multivariable methods. Duxbury Press; 1998. p. 281–316.
36. Lorente L, Martín MM, Abreu-González P, Ramos L, Argueso M, Cáceres JJ, et al. Association between serum malondialdehyde levels and mortality in patients with severe brain trauma injury. J Neurotrauma. 2015;32:1–6.
37. Lorente L, Martín MM, Pérez-Cejas A, González-Rivero AF, Argueso M, Ramos L, et al. Serum caspase-3 levels during the first week of traumatic brain injury. Med Intensiva. 2019 [published online ahead of print, 2019 Oct 30].
38. Carrasco G, Morillas J, Calizaya M, Baeza I, Molina R, Meije Y. ICU decision making based on Living Systematic Review strategy during SARS-CoV-2 pandemic. Results of a prospective case serie. Med Intensiva. 2020 [published online ahead of print, 2020 Jun 11].
39. Rodríguez A, Moreno G, Gómez J, Carbonell R, Picó-Plana E, Benavent Bofill C, et al., por el HJ23-COVID-19 working group; Listado de Investigadores del HJ23-COVID-19 Working Group. Laboratorio clínico; Epidemiología y prevención de la infección nosocomial; Departamento de enfermería UCI; Farmacia clínica; Médicos UCI. UCI Data-Analytics. Severe infection due to the SARS-CoV-2 coronavirus: Experience of a tertiary hospital with COVID-19 patients during the 2020 pandemic. Med Intensiva 2020 [published online ahead of print, 2020 Jun 19].
40. Serrano-Martínez JL, Machado-Casas JF, Redondo-Orts M, Manzano-Manzano F, Castaño-Pérez J, Pérez-Villares JM. Characteristics and results of a series of 59 patients with severe pneumonia due to COVID-19 admitted in the ICU. Med Intensiva. 2020 [published online ahead of print, 2020 Jun 17].